CL2017002474A1 - Combinaciones antihelmínticas y los métodos de usos de las mismas - Google Patents
Combinaciones antihelmínticas y los métodos de usos de las mismasInfo
- Publication number
- CL2017002474A1 CL2017002474A1 CL2017002474A CL2017002474A CL2017002474A1 CL 2017002474 A1 CL2017002474 A1 CL 2017002474A1 CL 2017002474 A CL2017002474 A CL 2017002474A CL 2017002474 A CL2017002474 A CL 2017002474A CL 2017002474 A1 CL2017002474 A1 CL 2017002474A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- prophylaxis
- treatment
- macrocyclic lactone
- anthelmintic
- Prior art date
Links
- 230000000507 anthelmentic effect Effects 0.000 title 1
- 150000002596 lactones Chemical class 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142304P | 2015-04-02 | 2015-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002474A1 true CL2017002474A1 (es) | 2018-03-23 |
Family
ID=57006415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002474A CL2017002474A1 (es) | 2015-04-02 | 2017-10-02 | Combinaciones antihelmínticas y los métodos de usos de las mismas |
Country Status (18)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019009977A2 (pt) * | 2016-11-16 | 2019-08-27 | Boehringer Ingelheim Animal Health Usa Inc | compostos depsipeptídicos anti-helmínticos |
| EP3579696B1 (en) * | 2017-02-08 | 2023-06-28 | Boehringer Ingelheim Animal Health USA Inc. | In vivo model for parasitic worm infection and methods for evaluating antiparasitic compounds, including compounds active against canine heartworm |
| BR112020010291A2 (pt) | 2017-11-23 | 2020-11-17 | Ceva Sante Animale | composição contendo moxidectina para tratamento de infestações de parasitas |
| RU2747149C9 (ru) * | 2017-11-29 | 2021-06-29 | ЗОЕТИС СЕРВИСИЗ ЭлЭлСи | Анти-эндопаразитарные депсипептиды |
| AR116524A1 (es) * | 2018-10-04 | 2021-05-19 | Elanco Tiergesundheit Ag | Potenciación de tratamiento de helmintos |
| AU2021335500A1 (en) | 2020-09-04 | 2023-05-04 | Elanco Us Inc. | Palatable formulations |
| GB202100635D0 (en) * | 2021-01-18 | 2021-03-03 | Liverpool School Tropical Medicine | Compounds and methods for treating or preventing dirofilaria infection in a mammal |
| WO2023073641A1 (en) | 2021-11-01 | 2023-05-04 | Boehringer Ingelheim Vetmedica Gmbh | Anthelmintic pyrrolopyridazine compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4134973A (en) | 1977-04-11 | 1979-01-16 | Merck & Co., Inc. | Carbohydrate derivatives of milbemycin and processes therefor |
| GB9300883D0 (en) | 1993-01-18 | 1993-03-10 | Pfizer Ltd | Antiparasitic agents |
| DE19520275A1 (de) * | 1995-06-02 | 1996-12-05 | Bayer Ag | Endoparasitizide Mittel |
| US20030129680A1 (en) | 2001-10-31 | 2003-07-10 | O'connor Thomas Patrick | Multi-analyte assay device |
| US20070042354A1 (en) | 2005-08-19 | 2007-02-22 | Engelhard Eric K | Detecting pathogens in companion animals |
| WO2008102232A1 (en) * | 2007-02-21 | 2008-08-28 | Pfizer Limited | Benzofuran antiparasitic agents |
| JP4734656B2 (ja) * | 2007-03-30 | 2011-07-27 | 国立大学法人群馬大学 | Ｐｆ１０２２類の製造法 |
| DE102008022520A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
| US8809268B2 (en) | 2008-10-29 | 2014-08-19 | The Regents Of The University Of California | Combination therapy to combat helminth resistance |
| BE1019407A5 (nl) | 2009-11-06 | 2012-07-03 | Momentum Animal Cure Bvba | Middel voor het uitdrijven van parasieten bij mensen, dieren en vogels. |
| WO2011095581A1 (en) | 2010-02-05 | 2011-08-11 | Intervet International B.V. | S piroindoline compounds for use as anthelminthi cs |
| WO2011115840A2 (en) | 2010-03-14 | 2011-09-22 | Ibis Biosciences, Inc. | Parasite detection via endosymbiont detection |
| RU2452180C2 (ru) * | 2010-08-31 | 2012-06-10 | Общество с ограниченной ответственностью "Научно-внедренческое предприятие "Астрафарм" | Комплексная антипаразитарная композиция |
| AU2010249226C1 (en) | 2010-12-08 | 2017-04-13 | Zoetis Services Llc | Anthelmintic formulation |
| AU2010101389C4 (en) | 2010-12-08 | 2017-03-02 | Jurox Pty Ltd | Anthelmintic formulation |
| WO2013017678A1 (en) | 2011-08-04 | 2013-02-07 | Intervet International B.V. | Novel spiroindoline compounds |
-
2016
- 2016-04-01 KR KR1020177031879A patent/KR20170132330A/ko not_active Withdrawn
- 2016-04-01 EP EP16721277.8A patent/EP3277303B1/en active Active
- 2016-04-01 MX MX2017012510A patent/MX381319B/es unknown
- 2016-04-01 WO PCT/US2016/025714 patent/WO2016161369A1/en not_active Ceased
- 2016-04-01 BR BR112017020975A patent/BR112017020975A2/pt not_active IP Right Cessation
- 2016-04-01 CN CN201680025471.5A patent/CN107567334A/zh active Pending
- 2016-04-01 RU RU2017138118A patent/RU2717545C2/ru active
- 2016-04-01 AU AU2016244022A patent/AU2016244022A1/en not_active Abandoned
- 2016-04-01 MY MYPI2017001452A patent/MY187835A/en unknown
- 2016-04-01 ES ES16721277T patent/ES2851345T3/es active Active
- 2016-04-01 US US15/089,282 patent/US10993988B2/en active Active
- 2016-04-01 SG SG11201708008TA patent/SG11201708008TA/en unknown
- 2016-04-01 CA CA2981489A patent/CA2981489A1/en not_active Abandoned
- 2016-04-01 JP JP2017551650A patent/JP6899330B2/ja not_active Expired - Fee Related
-
2017
- 2017-09-28 IL IL254783A patent/IL254783B/en active IP Right Grant
- 2017-09-29 PH PH12017501806A patent/PH12017501806A1/en unknown
- 2017-10-02 CL CL2017002474A patent/CL2017002474A1/es unknown
- 2017-11-02 CO CONC2017/0011284A patent/CO2017011284A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017012510A (es) | 2018-01-30 |
| MY187835A (en) | 2021-10-26 |
| EP3277303B1 (en) | 2020-12-02 |
| IL254783A0 (en) | 2017-12-31 |
| CN107567334A (zh) | 2018-01-09 |
| SG11201708008TA (en) | 2017-10-30 |
| AU2016244022A1 (en) | 2017-10-26 |
| CA2981489A1 (en) | 2016-10-06 |
| WO2016161369A1 (en) | 2016-10-06 |
| EP3277303A1 (en) | 2018-02-07 |
| US10993988B2 (en) | 2021-05-04 |
| US20170020955A1 (en) | 2017-01-26 |
| RU2717545C2 (ru) | 2020-03-24 |
| BR112017020975A2 (pt) | 2018-07-10 |
| RU2017138118A (ru) | 2019-05-06 |
| CO2017011284A2 (es) | 2018-01-31 |
| JP6899330B2 (ja) | 2021-07-07 |
| PH12017501806A1 (en) | 2018-04-11 |
| ES2851345T3 (es) | 2021-09-06 |
| MX381319B (es) | 2025-03-12 |
| RU2017138118A3 (cg-RX-API-DMAC10.html) | 2019-07-24 |
| JP2018510195A (ja) | 2018-04-12 |
| IL254783B (en) | 2020-11-30 |
| KR20170132330A (ko) | 2017-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017011284A2 (es) | Combinaciones antihelmínticas y métodos de uso de ellas | |
| CL2016000424A1 (es) | Métodos y composiciones para el arn-guiado tratamiento de la infección por vih | |
| CL2016000698A1 (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
| MX385876B (es) | Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante. | |
| CL2017003404A1 (es) | Compuestos antibacterianos | |
| UY37563A (es) | Aislados de bacillus y usos de los mismos | |
| CO7350655A2 (es) | Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih | |
| MX2017008720A (es) | Derivados y metodos para tratamiento de las infecciones por hepatitis b. | |
| NI201600051A (es) | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores | |
| CL2012002782A1 (es) | Compuestos derivados de pirazol-4-il-heterociclil-carboxamida, inhibidores de los trastornos mediados por las quinasas pim-1, pim-2 y pim-3; composición farmacéutica; mètodo de tratamiento; y su uso para el tratamiento del càncer, trastornos inmunes, enfermedades cardiovasculares e infecciones virales , entre otros. | |
| MX2017004600A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| CL2015001562A1 (es) | Método para obtener una vacuna de mycoplasma. | |
| CU20170153A7 (es) | Compuestos tricíclicos útiles como inhibidores de la fosfodiesterasa | |
| IL253619B (en) | Encapsulation of high potency active agents | |
| MX2019011271A (es) | Compuestos y metodos para el tratamiento de enfermedades parasitarias. | |
| CL2017000178A1 (es) | Compuestos para usar en el tratamiento antihelmíntico | |
| CO2017005968A2 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| CL2017001025A1 (es) | Compuestos para usarse en el tratamiento antihelmíntico | |
| CR20160235A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| MX2018004304A (es) | DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß. | |
| CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| CL2018000253A1 (es) | Respuesta inmunitaria potenciada de las especies porcinas | |
| MX375318B (es) | Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina.. | |
| PE20151726A1 (es) | Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles | |
| CR20160369A (es) | Composiciones para uso en el tratamiento de afecciones alérgicas |